May 15, 2018—The technology to edit the genomes of living things is advancing rapidly. How do we decide when not to do the things that we can? Applications in laboratory mice would allow the assembly of complex genotypes that were once unthinkable due to cost, time, and number of animals. Such applications could improve drug testing and mouse models of complex human genetic diseases. Despite these benefits, many have raised concerns about unintended consequences of the release of transgenic organisms.
April 16, 2018—Given the growing demand for deep sea metals created by electronic and green technologies, scientists are faced with decisions about whether to engage in baseline and impacts research that enables development of a new extraction industry, and whether to contribute expertise to the development of environmental protections and guidelines. Discussions will address the ethical and societal challenges of exploitation in a relatively unknown realm.
April 4, 2018 – UC San Diego Altman Clinical and Translational Research Institute (ACTRI) and Pfizer's Center for Therapeutic Innovation (CTI) are seeking pre-proposals from UC San Diego Health Sciences faculty interested in a drug discovery collaboration with the Pfizer CTI. Proposals are sought for biotherapeutic and small-molecule targets.
March 26, 2018 – Information from some of the largest online communities, such as Facebook and Twitter are public domain. Specific information can be retrieved to access trends in human behavior, including important health issues such as sub-stance abuse behavior. The manner in which the data is collected, analyzed, and published present many ethical concerns. Could access to certain treatments be denied due to what we share on public sites? How can anonymity be guaranteed when the research is published?
March 8, 2018 – The University of California Center for Accelerated Innovation (UC CAI) anticipates awarding multiple Technology Development Grants worth $200,000 each for development of drugs, devices (including wireless), diagnostics, and tools that address heart, lung and blood diseases. Most technologies will be awarded at $200,000, however, technologies that would substantially benefit from up to $400,000 may submit an application at both the $200,000 and $400,000 funding levels. Pre-application submission period is March 19-23, 2018.
Read the NHLBI RFA
Eligibility: Faculty in all series and ranks at UC Davis, Irvine, Los Angeles, San Diego and San Francisco are eligible. Postdoctoral scholars are eligible to submit applications as Co-PI with a faculty PI.
About UC CAI
UC CAI is a collaboration of the five UC medical campuses, including UC San Diego. The mission of UC CAI is to translate NHLBI- and NIDA-funded discoveries to improve health and health care and address unmet medical needs. The UC CAI is based at UCLA and supported by NIHLB, NIDA and the CTSAs at UC Davis, Irvine, Los Angeles, San Diego (ACTRI) and San Francisco.
February 27, 2018 – The 2018 Southern California Regional Dissemination Implementation & Improvement (DII) Science Symposium will take place on Thursday, June 28, 2018 at the California Endowment in downtown Los Angeles. The theme is “Creating Learning Health and Population Health Systems.” Host institutions include the Clinical and Translational Science Institutes at UCLA, USC, UC San Diego, UCI and UCR, the Gehr Family Center for Health Systems Science along with the Los Angeles County Health Agency, Kaiser Permanente Southern California, the Department of Veterans Affairs Greater Los Angeles Healthcare System, and RAND.
February 27, 2018 – High energy, long life, rechargeable batteries are considered an important technological opportunity to reduce production of greenhouse gases. What standards should be set for safety of new energy storage technologies? And who should enforce those standards? Join us for this program to learn about these exciting developments as well as discussing how best to meet potential social and ethical challenges.
January 23, 2018 – The goal of the Last Gift study is to better understand how HIV remains hidden from both the person’s immune system and current HIV therapy. By discontinuing HIV therapy from terminally-ill volunteers, the return of the virus can be tracked with periodic blood draws, and the residual reservoirs can subsequently be identified at autopsy. Results of such studies could help develop ways to clear these reservoirs with future therapies. What are the challenges to ensuring that these patient can give truly informed consent to participate in this human subjects research? What measures are already in place to protect the interests of the patient and her or his family? How can we achieve the goals of the research while still respecting the autonomy and dignity of these terminally ill patients?
January 18, 2018 – UC San Diego Altman Clinical and Translational Research Institute (ACTRI) invites researchers and staff to the Translational Science Symposium on Thursday, April 5, 2018, at the ACTRI Building. Dr. Robert Califf, a former Food and Drug Administration (FDA) Commissioner, is scheduled to deliver the keynote talk at 4 p.m. in the ACTRI Auditorium. Dr. Califf is a nationally and internationally recognized expert in cardiovascular medicine and former vice chancellor of clinical and translational research at Duke University. He served as FDA Commissioner from February 2016-January 2017. This annual symposium features presentations by ACTRI-supported researchers and a distinguished keynote speaker, as well as information about ACTRI resources.